Azizi Fereidoun, Navai Lida, Fattahi Farid
Endocrine Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, I.R. Iran.
Int J Vitam Nutr Res. 2002 Oct;72(5):291-5. doi: 10.1024/0300-9831.72.5.291.
In a previous study in 1983, goiter was found to be endemic in Shahriar, Iran. Iodized salt has been distributed in the region for the past 12 years, and the present study was performed to examine the effect of iodide supplementation on indicators of iodine deficiency (IDD) and thyroid antibodies.
DESIGN & METHODS: A total of 3164 people, 58% women and 42% men, were selected by random sampling from the Shahriar area. Goiter was staged according to World Health Organization guidelines. Urinary iodine was measured by a digestion method, and thyroid hormone measurements were done by radioimmunoassay. The results were compared with those of 1983.
Goiter prevalence before and after iodine supplementation was 50 and 40% in men, 70 and 51% in women, and 60 and 47% in the whole community, respectively (p < 0.001). A decrease in the prevalence of goiter was observed especially in younger individuals. The mean urinary iodine excretion was 7.6 and 18.5 micrograms/dL, before and after iodine supplementation. In 1983, the urinary iodine in 47.5% of the population studied was between 2 to 5 micrograms/dL, while in 1995, 65% of the population studied had urinary iodine between 10 to 25 micrograms/dL, 12 years after iodine supplementation. Mean serum T4, T3, and thyroid-stimulating hormone (TSH) were normal before and after intervention. There was no significant change in occurrence of positive antibodies, or of hypo- and hyperthyroidism, following iodine supplementation.
The result of this study shows that the use of iodized salt causes an increase in excreted urinary iodine and a decrease in the prevalence of thyroid goiter, especially in younger age groups. Consumption of iodized salt with 40 parts per million (ppm) iodine has not caused increased prevalence of thyroid dysfunction in this area.
在1983年的一项前期研究中,发现伊朗沙赫里亚尔地区存在地方性甲状腺肿。在过去12年里该地区一直供应加碘盐,本研究旨在检验补充碘对碘缺乏病(IDD)指标及甲状腺抗体的影响。
通过随机抽样从沙赫里亚尔地区选取了3164人,其中女性占58%,男性占42%。根据世界卫生组织的指南对甲状腺肿进行分期。采用消化法测量尿碘,通过放射免疫分析法测定甲状腺激素。将结果与1983年的结果进行比较。
补充碘前后,男性甲状腺肿患病率分别为50%和40%,女性分别为70%和51%,整个社区分别为60%和47%(p < 0.001)。尤其在年轻人中观察到甲状腺肿患病率有所下降。补充碘前后尿碘平均排泄量分别为7.6和18.5微克/分升。1983年,所研究人群中47.5%的尿碘在2至5微克/分升之间,而在补充碘12年后的1995年,所研究人群中65%的尿碘在10至25微克/分升之间。干预前后血清总甲状腺素(T4)、三碘甲状腺原氨酸(T3)和促甲状腺激素(TSH)均值均正常。补充碘后,阳性抗体的出现以及甲状腺功能减退和亢进的发生率均无显著变化。
本研究结果表明,食用加碘盐可使尿碘排泄增加,甲状腺肿患病率降低,尤其是在年轻人群体中。食用含碘量为百万分之四十(ppm)的加碘盐并未导致该地区甲状腺功能障碍患病率增加。